Compare Microchip Technology Inc. (MCHP) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Microchip Technology Inc. vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Microchip Technology Inc. trades at $69.73 (market cap $40.27B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Microchip Technology Inc. is far larger — about 41.4× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Microchip Technology Inc. pays a 2.45% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Microchip Technology Inc. for 63 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| MCHP | MRVI | |
|---|---|---|
Market Cap | $40.27B | $972.90M |
Volume | 6,570,711 | 4,325,710 |
Sector | Technology | Health |
52-Week High | $102.97 | $9.00 |
52-Week Low | $49.02 | $2.83 |
Typical Hold Time | 63 Days | 0 Days |
Enterprise Value | $45.40B | $1.08B |
Dividend Yield | 2.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Microchip Technology (MCHP) trades at $71.25, down 3.49% today, with a bearish technical signal from moving averages. The company shows mixed fundamentals with strong recent earnings beats but negative net income in 2025. Recent developments include the acquisition of Hailo and expansion of Ethernet and power portfolios targeting automotive and data center markets. Analyst consensus remains strongly bullish with a $110.50 price target despite current weakness.
MCHP faces near-term headwinds from cyclical semiconductor demand but maintains long-term growth potential through AI infrastructure and automotive connectivity. High valuation ratios (P/E 109.06) and significant debt ($5.63B) present risks, while institutional accumulation and product expansion provide upside catalysts. The stock offers 55% upside to consensus target if execution improves.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Microchip Technology Inc.
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
